Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) (NCT03407144)

🧪 Interventions in This Study

• pembrolizumab (BIOLOGICAL)
• doxorubicin (DRUG)
• vinblastine (DRUG)
• dacarbazine (DRUG)
• cyclophosphamide (DRUG)
• vincristine (DRUG)
• prednisone/prednisolone (DRUG)
• bleomycin (DRUG)
• etoposide (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (93 Sites)

Showing the first 25 of 93 sites.

• Children's Hospital of Alabama ( Site 0023) — Birmingham, Alabama
• Phoenix Childrens Hospital ( Site 0034) — Phoenix, Arizona
• Arkansas Children's Hospital ( Site 0046) — Little Rock, Arkansas
• Kaiser - Orange County ( Site 0084) — Anaheim, California
• Kaiser Permanente ( Site 0082) — Downey, California
• Kaiser - Fontana ( Site 0083) — Fontana, California
• MemorialCare Health System - Long Beach Medical Center-Cherese Mari Laulhere Children's Village ( Si — Long Beach, California
• Kaiser Permanente Downey Medical Center ( Site 0024) — Los Angeles, California
• Kaiser Permanente - Oakland ( Site 0047) — Oakland, California
• Kaiser Permanente - Roseville ( Site 0080) — Roseville, California
• Kaiser Permanente - Santa Clara ( Site 0079) — Santa Clara, California
• Children's Hospital - Colorado ( Site 0028) — Aurora, Colorado
• Connecticut Children's Medical Center ( Site 0045) — Hartford, Connecticut
• Yale Cancer Center ( Site 0061) — New Haven, Connecticut
• Children's National Medical Center ( Site 0090) — Washington D.C., District of Columbia
• University of Florida ( Site 0051) — Gainesville, Florida
• Memorial Regional Hospital/Joe DiMaggio Children's Hospital ( Site 0048) — Hollywood, Florida
• Arnold Palmer Hospital ( Site 0065) — Orlando, Florida
• Children's Healthcare of Atlanta at Egleston ( Site 0033) — Atlanta, Georgia
• University of Chicago ( Site 0066) — Chicago, Illinois
• Riley Hospital for Children ( Site 0091) — Indianapolis, Indiana
• University of Kentucky Markey Cancer Center ( Site 0057) — Lexington, Kentucky
• University of Louisville-Norton Children's Hospital ( Site 0059) — Louisville, Kentucky
• Johns Hopkins University ( Site 0025) — Baltimore, Maryland
• Children's Hospital of Michigan ( Site 0056) — Detroit, Michigan

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Hodgkin Lymphoma

• Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma — Detroit, Michigan
• PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma — Houston, Texas
• Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma — Salt Lake City, Utah
• A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) — Detroit, Michigan
• Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL — Chicago, Illinois

Explore by condition: All Hodgkin Lymphoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.